# OnCo record rptr-1-201 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rptr-1-201/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rptr-1-201" ;
  schema:name "RPTR-1-201"@en ;
  schema:description "RPTR-1-201 is an experimental bispecific protein from Repertoire Immune Medicines, in phase 1 trials for advanced solid tumours in people with the HLA-A*02:01 tissue type."@en ;
  schema:url <https://onco.cc/drugs/rptr-1-201/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.repertoire.com/programs/pipeline>, <https://www.repertoire.com/about/press-releases/repertoire-immune-medicines-announces-fda-fast-track-designation-for-its-investigational-immune-medicine-rptr-1-201>, <https://clinicaltrials.gov/study/NCT07293754> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "TCR bispecific (an engineered T-cell receptor fused to an anti-CD3 domain)" ;
  onco:targets <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/repertoire-immune-medicines/> ;
  onco:trials <https://onco.cc/trials/nct07293754/> .